-
Phase 2 expansion cohort data supports ongoing Phase 3 trial
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present additional data on its lead partnered asset, monalizumab, at the ESMO Immuno-oncology Virtual Congress being held from Dec. 9-12, 2020. Monalizumab is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells.
The presentation will include updated results from a Phase 2 study investigating the combination of monalizumab and cetuximab in patients with recurrent or metastatic head and neck squamous cell cancer (R/M SCCHN) who have been previously treated with a platinum-based chemotherapy and PD-(L)1 inhibitor.
The e-poster presentation (#81P, abstract #235) entitled, “Monalizumab in combination with cetuximab post platinum and anti-PD-(L)1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Updated results from a phase 2 trial” will be available on Dec. 9th.
As recently announced, AstraZeneca dosed the first patient in its Phase 3 clinical trial, INTERLINK-1, evaluating monalizumab in combination with cetuximab in R/M SCCHN patients who have been previously treated with a platinum-based chemotherapy and PD-(L)1 inhibitors.